Health Condition 1: A150- Tuberculosis of lung
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Sputum positive for M. tuberculosis either by sputum smear microscopy or by (CBNAAT) 2. Aged 18 years or more 3. Has BMI between 14 -18.5 Kg/m2 4. No prior history of ATT (i.e. 5. At least 1 sputum should be RMP sensitive by CBNAAT 6. Is willing to have an HIV test. 7. Female of child bearing age with no intention to become pregnant during the study period 8. Residing in Ballabgarh Block.
Exclusion criteria
Exclusion criteria: 5. Sero-positive for HIV virus antibodies either by ELISA or by rapid test 6. Is pregnant or lactating 7. Known case of diabetes mellitus/RBS > 200mg /FBS >126 mg/dl 8. Poor general condition or has any condition (social or medical) which in the opinion of the investigator would make trial participation unreliable or unsafe. 9. Is allergic to the constituents of EDNS such as peanut etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Sputum bacteriological conversion rate 2.Time to bacteriological conversion of sputum 3.Cure rate at the end of six months of anti-tuberculous treatment (ATT) Timepoint: 1. Sputum AFB examination every fortnight till it becomes negative 2. Sputum culture at the time sputum becomes negative to conform sputum conversion 3.Cure at the end of six months of anti-tuberculous treatment (ATT) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in weight and BMI over the period of intervention and six months of follow up after end of intervention. 2. Change in biochemical nutritional markers (Serum Zinc, Iron, retinol, 25 hydroxy cholecalciferol) over the period of intervention 6. Proportion of subjects finding EDNS acceptable 7. Change in immunological markers following the intervention 8. Frequency of adverse events due to EDNSTimepoint: 1. Weight and BMI- monthly till six months of treatment and once 6 months after completion of treatment 2. Biochemical nutrition markers- At baseline, 2 and 6 months 3. Acceptability of EDNS- after 1 month 4. Immunological markers: at baseline, months 2, 6 and 6 months after completion of treatment 4. Adverse event- fortnightly till intervention continues | — |
Countries
India
Contacts
All India Institute of Medical Sciences, New Delhi